$5.5m raised from rights issue, page-72

Zaskar you are correct re. SC1 I was trying to multi-task :-)

Another big kicker that could come out of the shadows is another combination trial with SM6. While Patrys have already stated now that Amgen have stepped in they wont be turning attention to find partners that doesn't mean they wont be approached if Onyx haven't pushed a exclusivity clause on the agreement - that would of been updated if it had occurred & it also wouldn't of come at no cost. It's fairly common for multiple combination trials to run concurrently. With the tight & fiercely competitive MM market alongside Patrys data showing other treatments that had previously failed then giving response post SM6 surely stirs some interest amongst that niche field.

It was previously stated interest from multiple pharmaceutical & biotechnology companies.

Amgen/Onyx stepped up based on 3rd Cohorts data & less than a week after FDA granted ODD. Does Kyprolis stepping in here create an impetus for its competitors that also showed response after SM6 treatment ? Either way Amgen jumped the gun ahead of what has turned out to be very impressive data from the 4th cohort & Patrys now standing firmly with $10M cash behind it.

Will another party move here ?